Epigenetic activation of POTE genes in ovarian cancer

Ashok Sharma, Mustafa Albahrani, Wa Zhang, Christina N. Kufel, Smitha R. James, Kunle Odunsi, David Klinkebiel, Adam R. Karpf

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The POTE gene family consists of 14 homologous genes localized to autosomal pericentromeres, and a sub-set of POTEs are cancer-testis antigen (CTA) genes. POTEs are over-expressed in epithelial ovarian cancer (EOC), including the high-grade serous subtype (HGSC), and expression of individual POTEs correlates with chemoresistance and reduced survival in HGSC. The mechanisms driving POTE overexpression in EOC and other cancers is unknown. Here, we investigated the role of epigenetics in regulating POTE expression, with a focus on DNA hypomethylation. Consistent with their pericentromeric localization, Pan-POTE expression in EOC correlated with expression of the pericentromeric repeat NBL2, which was not the case for non-pericentromeric CTAs. POTE genomic regions contain LINE-1 (L1) sequences, and Pan-POTE expression correlated with both global and POTE-specific L1 hypomethylation in EOC. Analysis of individual POTEs using RNA-seq and DNA methylome data from fallopian tube epithelia (FTE) and HGSC revealed that POTEs C, E, and F have increased expression in HGSC in conjunction with DNA hypomethylation at 5’ promoter or enhancer regions. Moreover, POTEs C/E/F showed additional increased expression in recurrent HGSC in conjunction with 5’ hypomethylation, using patient-matched samples. Experiments using decitabine treatment and DNMT knockout cell lines verified a functional contribution of DNA methylation to POTE repression, and epigenetic drug combinations targeting histone deacetylases (HDACs) and histone methyltransferases (HMTs) in combination with decitabine further increased POTE expression. In summary, several alterations of the cancer epigenome, including pericentromeric activation, global and locus-specific L1 hypomethylation, and locus-specific 5’ CpG hypomethylation, converge to promote POTE expression in ovarian cancer.

Original languageEnglish (US)
Pages (from-to)185-197
Number of pages13
JournalEpigenetics
Volume14
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

decitabine
Epigenomics
Ovarian Neoplasms
Transcriptional Activation
Epigenetic Repression
DNA
Genes
Histone Deacetylases
Fallopian Tubes
Testicular Neoplasms
DNA Methylation
Drug Combinations
Drug Delivery Systems
Neoplasms
Epithelium
RNA
Antigens
Cell Line
Survival
Ovarian epithelial cancer

Keywords

  • DNA hypomethylation
  • LINE1
  • Ovarian cancer
  • POTE
  • high-grade serous ovarian cancer
  • pericentromeres

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

Sharma, A., Albahrani, M., Zhang, W., Kufel, C. N., James, S. R., Odunsi, K., ... Karpf, A. R. (2019). Epigenetic activation of POTE genes in ovarian cancer. Epigenetics, 14(2), 185-197. https://doi.org/10.1080/15592294.2019.1581590

Epigenetic activation of POTE genes in ovarian cancer. / Sharma, Ashok; Albahrani, Mustafa; Zhang, Wa; Kufel, Christina N.; James, Smitha R.; Odunsi, Kunle; Klinkebiel, David; Karpf, Adam R.

In: Epigenetics, Vol. 14, No. 2, 01.02.2019, p. 185-197.

Research output: Contribution to journalArticle

Sharma, A, Albahrani, M, Zhang, W, Kufel, CN, James, SR, Odunsi, K, Klinkebiel, D & Karpf, AR 2019, 'Epigenetic activation of POTE genes in ovarian cancer', Epigenetics, vol. 14, no. 2, pp. 185-197. https://doi.org/10.1080/15592294.2019.1581590
Sharma A, Albahrani M, Zhang W, Kufel CN, James SR, Odunsi K et al. Epigenetic activation of POTE genes in ovarian cancer. Epigenetics. 2019 Feb 1;14(2):185-197. https://doi.org/10.1080/15592294.2019.1581590
Sharma, Ashok ; Albahrani, Mustafa ; Zhang, Wa ; Kufel, Christina N. ; James, Smitha R. ; Odunsi, Kunle ; Klinkebiel, David ; Karpf, Adam R. / Epigenetic activation of POTE genes in ovarian cancer. In: Epigenetics. 2019 ; Vol. 14, No. 2. pp. 185-197.
@article{39d5a59a1546491d968f069fad56123b,
title = "Epigenetic activation of POTE genes in ovarian cancer",
abstract = "The POTE gene family consists of 14 homologous genes localized to autosomal pericentromeres, and a sub-set of POTEs are cancer-testis antigen (CTA) genes. POTEs are over-expressed in epithelial ovarian cancer (EOC), including the high-grade serous subtype (HGSC), and expression of individual POTEs correlates with chemoresistance and reduced survival in HGSC. The mechanisms driving POTE overexpression in EOC and other cancers is unknown. Here, we investigated the role of epigenetics in regulating POTE expression, with a focus on DNA hypomethylation. Consistent with their pericentromeric localization, Pan-POTE expression in EOC correlated with expression of the pericentromeric repeat NBL2, which was not the case for non-pericentromeric CTAs. POTE genomic regions contain LINE-1 (L1) sequences, and Pan-POTE expression correlated with both global and POTE-specific L1 hypomethylation in EOC. Analysis of individual POTEs using RNA-seq and DNA methylome data from fallopian tube epithelia (FTE) and HGSC revealed that POTEs C, E, and F have increased expression in HGSC in conjunction with DNA hypomethylation at 5’ promoter or enhancer regions. Moreover, POTEs C/E/F showed additional increased expression in recurrent HGSC in conjunction with 5’ hypomethylation, using patient-matched samples. Experiments using decitabine treatment and DNMT knockout cell lines verified a functional contribution of DNA methylation to POTE repression, and epigenetic drug combinations targeting histone deacetylases (HDACs) and histone methyltransferases (HMTs) in combination with decitabine further increased POTE expression. In summary, several alterations of the cancer epigenome, including pericentromeric activation, global and locus-specific L1 hypomethylation, and locus-specific 5’ CpG hypomethylation, converge to promote POTE expression in ovarian cancer.",
keywords = "DNA hypomethylation, LINE1, Ovarian cancer, POTE, high-grade serous ovarian cancer, pericentromeres",
author = "Ashok Sharma and Mustafa Albahrani and Wa Zhang and Kufel, {Christina N.} and James, {Smitha R.} and Kunle Odunsi and David Klinkebiel and Karpf, {Adam R.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1080/15592294.2019.1581590",
language = "English (US)",
volume = "14",
pages = "185--197",
journal = "Epigenetics",
issn = "1559-2294",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - Epigenetic activation of POTE genes in ovarian cancer

AU - Sharma, Ashok

AU - Albahrani, Mustafa

AU - Zhang, Wa

AU - Kufel, Christina N.

AU - James, Smitha R.

AU - Odunsi, Kunle

AU - Klinkebiel, David

AU - Karpf, Adam R.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The POTE gene family consists of 14 homologous genes localized to autosomal pericentromeres, and a sub-set of POTEs are cancer-testis antigen (CTA) genes. POTEs are over-expressed in epithelial ovarian cancer (EOC), including the high-grade serous subtype (HGSC), and expression of individual POTEs correlates with chemoresistance and reduced survival in HGSC. The mechanisms driving POTE overexpression in EOC and other cancers is unknown. Here, we investigated the role of epigenetics in regulating POTE expression, with a focus on DNA hypomethylation. Consistent with their pericentromeric localization, Pan-POTE expression in EOC correlated with expression of the pericentromeric repeat NBL2, which was not the case for non-pericentromeric CTAs. POTE genomic regions contain LINE-1 (L1) sequences, and Pan-POTE expression correlated with both global and POTE-specific L1 hypomethylation in EOC. Analysis of individual POTEs using RNA-seq and DNA methylome data from fallopian tube epithelia (FTE) and HGSC revealed that POTEs C, E, and F have increased expression in HGSC in conjunction with DNA hypomethylation at 5’ promoter or enhancer regions. Moreover, POTEs C/E/F showed additional increased expression in recurrent HGSC in conjunction with 5’ hypomethylation, using patient-matched samples. Experiments using decitabine treatment and DNMT knockout cell lines verified a functional contribution of DNA methylation to POTE repression, and epigenetic drug combinations targeting histone deacetylases (HDACs) and histone methyltransferases (HMTs) in combination with decitabine further increased POTE expression. In summary, several alterations of the cancer epigenome, including pericentromeric activation, global and locus-specific L1 hypomethylation, and locus-specific 5’ CpG hypomethylation, converge to promote POTE expression in ovarian cancer.

AB - The POTE gene family consists of 14 homologous genes localized to autosomal pericentromeres, and a sub-set of POTEs are cancer-testis antigen (CTA) genes. POTEs are over-expressed in epithelial ovarian cancer (EOC), including the high-grade serous subtype (HGSC), and expression of individual POTEs correlates with chemoresistance and reduced survival in HGSC. The mechanisms driving POTE overexpression in EOC and other cancers is unknown. Here, we investigated the role of epigenetics in regulating POTE expression, with a focus on DNA hypomethylation. Consistent with their pericentromeric localization, Pan-POTE expression in EOC correlated with expression of the pericentromeric repeat NBL2, which was not the case for non-pericentromeric CTAs. POTE genomic regions contain LINE-1 (L1) sequences, and Pan-POTE expression correlated with both global and POTE-specific L1 hypomethylation in EOC. Analysis of individual POTEs using RNA-seq and DNA methylome data from fallopian tube epithelia (FTE) and HGSC revealed that POTEs C, E, and F have increased expression in HGSC in conjunction with DNA hypomethylation at 5’ promoter or enhancer regions. Moreover, POTEs C/E/F showed additional increased expression in recurrent HGSC in conjunction with 5’ hypomethylation, using patient-matched samples. Experiments using decitabine treatment and DNMT knockout cell lines verified a functional contribution of DNA methylation to POTE repression, and epigenetic drug combinations targeting histone deacetylases (HDACs) and histone methyltransferases (HMTs) in combination with decitabine further increased POTE expression. In summary, several alterations of the cancer epigenome, including pericentromeric activation, global and locus-specific L1 hypomethylation, and locus-specific 5’ CpG hypomethylation, converge to promote POTE expression in ovarian cancer.

KW - DNA hypomethylation

KW - LINE1

KW - Ovarian cancer

KW - POTE

KW - high-grade serous ovarian cancer

KW - pericentromeres

UR - http://www.scopus.com/inward/record.url?scp=85062466171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062466171&partnerID=8YFLogxK

U2 - 10.1080/15592294.2019.1581590

DO - 10.1080/15592294.2019.1581590

M3 - Article

C2 - 30764732

AN - SCOPUS:85062466171

VL - 14

SP - 185

EP - 197

JO - Epigenetics

JF - Epigenetics

SN - 1559-2294

IS - 2

ER -